Findings

What do systematic reviews say?

66 questions · 67 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 10.4%GRADE not reported 4 · 6%Very low 28 · 41.8%Low 18 · 26.9%Moderate 10 · 14.9%High 0 · 0%

Selective serotonin reuptake inhibitors vs placebo

Frequency of attacks Per week (over 2 weeks) · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

Duration of attacks per day (minutes) · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selective serotonin reuptake inhibitors vs placebo

Proportion of participants with adverse effects ‐ measured over 8 weeks · primary Raynaud's phenomenon

It is very uncertain whether selective serotonin reuptake inhibitors changes adverse events (over 4 weeks) compared with placebo (very low certainty).

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
RR 1.54 [0.89, 2.66]
1 study · 41 participants
Very low

Selective serotonin reuptake inhibitors vs placebo

RCS · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

> 50% reduction in depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Depressive symptoms · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
15 participants
Very low

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Seizure frequency · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
15 participants
Very low

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Treatment withdrawal · people with epilepsy and depression

It is very uncertain whether selective serotonin reuptake inhibitors changes withdrawals compared with cognitive behavioural therapy (very low certainty).

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
RR 0.44 [0.05, 3.85]
15 participants
Very low

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Cognitive function · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Post‐treatment quality of life (QOLIE‐31 score, which has a range of 0‐200, with higher score indicates better quality of life) ( · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
15 participants
Very low

Selective serotonin reuptake inhibitors vs cognitive behavioural therapy

Adverse effects ‐ adverse event profile · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Selective serotonin reuptake inhibitors vs placebo

Outcomes (2‐6 months post‐treatment) · adults with panic disorder

The review found no eligible studies for this question.

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Selective serotonin reuptake inhibitors vs placebo

Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder

Selective serotonin reuptake inhibitors may leads to lower failure to respond compared with placebo (low certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 0.75 [0.67, 0.84]
21 studies · 4000 participants
Low

Selective serotonin reuptake inhibitors vs placebo

Leaving the study early · adults with panic disorder

Selective serotonin reuptake inhibitors showed no clear difference in total number of dropouts compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 0.99 [0.9, 1.09]
23 studies · 4302 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Failure to remit at endpoint · adults with panic disorder

Selective serotonin reuptake inhibitors probably leads to lower failure to remit compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 0.81 [0.75, 0.88]
16 studies · 3339 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

panic symptoms · adults with panic disorder

2 findings from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1625 participants
Moderate
Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1255 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Withdrawals due to adverse events · adults with panic disorder

Selective serotonin reuptake inhibitors probably leads to higher number of dropouts due to adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Antidepressants versus placebo for panic disorder in adults 2018 · Cochrane Headline outcomes only
RR 1.45 [1.16, 1.81]
22 studies · 4131 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Subjective sleep quality or quantity · adults with insomnia

1 finding from 1 review

Antidepressants for insomnia in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 135 participants
Low